Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer

Chemohormonal therapy is a standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC); however, there are no biomarkers to guide clinical decisions regarding therapeutic options. We aimed to evaluate the clinical utility of serial circulating tumor DNA (ctDNA) sequencing in early pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xinxing, Fei, Xiaochen, Wang, Jialin, Dong, Yanhao, Fan, Liancheng, Yang, Bin, Chen, Wei, Gong, Yiming, Xia, Binbin, Zhu, Hanjing, Wu, Fan, Wang, Yanqing, Dong, Liang, Zhu, Yinjie, Pan, Jiahua, Yao, Xudong, Dong, Baijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236461/
https://www.ncbi.nlm.nih.gov/pubmed/37247504
http://dx.doi.org/10.1016/j.tranon.2023.101701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236461/
https://www.ncbi.nlm.nih.gov/pubmed/37247504
http://dx.doi.org/10.1016/j.tranon.2023.101701

Ejemplares similares